Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio.

ZMapp™ Information Sheet

ZMapp™ Frequently Asked Questions

June 10, 2015 - Mapp signs contract with Public Health Agency of Canada

February 27, 2015 - Mapp Bio Clinical Trials Press Release

February 6, 2015 - LeafBio, Inc. submitted an Investigational New Drug (IND) application for clinical evaluation of ZMapp™ to the Food and Drug Administration (FDA) on February 3, 2015.

December 22, 2014 - Washington Post - The best innovations of 2014: ZMapp, for offering clues to a potential cure for Ebola

October 10, 2014 - Status Update on ZMapp™


Mapp Biopharmaceutical, Inc.
6160 Lusk Blvd. # C105
San Diego, CA 92121
phone: 858 625 0335
fax: 800 372 2176

Media Inquiries

FCOI Policy



Product Development
Product Development

�2012 Mapp Biopharmaceutical, Inc. All rights reserved.